Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling.
Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling.
复制标题
DOI：
10.1038/s41467-020-20383-x
复制
发表时间：
2021-01-04
影响因子：
16.6
通讯作者：
Sadtler K
中科院分区：
文献类型：
--
作者：
Klumpp-Thomas C;Kalish H;Drew M;Hunsberger S;Snead K;Fay MP;Mehalko J;Shunmugavel A;Wall V;Frank P;Denson JP;Hong M;Gulten G;Messing S;Hicks J;Michael S;Gillette W;Hall MD;Memoli MJ;Esposito D;Sadtler K
The extent of SARS-CoV-2 infection throughout the United States population is currently unknown. High quality serology is key to avoiding medically costly diagnostic errors, as well as to assuring properly informed public health decisions. Here, we present an optimized ELISA-based serology protocol, from antigen production to data analyses, that helps define thresholds for IgG and IgM seropositivity with high specificities. Validation of this protocol is performed using traditionally collected serum as well as dried blood on mail-in blood sampling kits. Archival (pre-2019) samples are used as negative controls, and convalescent, PCR-diagnosed COVID-19 patient samples serve as positive controls. Using this protocol, minimal cross-reactivity is observed for the spike proteins of MERS, SARS1, OC43 and HKU1 viruses, and no cross reactivity is observed with anti-influenza A H1N1 HAI. Our protocol may thus help provide standardized, population-based data on the extent of SARS-CoV-2 seropositivity, immunity and infection. Understanding the infection parameters and host responses against SARS-CoV-2 require data from large cohorts using standardized methods. Here, the authors optimize a serum ELISA protocol that has minimal cross-reactivity and flexible sample collection workflow in an attempt to standardize data generation and help inform on COVID-19 pandemic and immunity.
登录
查看更多内容
影响因子：
12.7
作者：
PASS, KA;SCHEDLBAUER, LM;GLEBATIS, DM
通讯作者：
GLEBATIS, DM
SARS-COV峰值蛋白的受体结合结构域可诱导高度有效的中和抗体：对开发亚基疫苗的影响。
DOI：
10.1016/j.bbrc.2004.09.106
发表时间：
2004-11-12
影响因子：
3.1
作者：
He Y;Zhou Y;Liu S;Kou Z;Li W;Farzan M;Jiang S
通讯作者：
Jiang S
影响因子：
2.2
作者：
Roy, Vicky;Fischinger, Stephanie;Alter, Galit
通讯作者：
Alter, Galit
DOI：
10.20506/rst.17.2.1119
发表时间：
1998-08-01
影响因子：
0.6
作者：
Jacobson, RH
通讯作者：
Jacobson, RH
影响因子：
--
作者：
Stadlbauer, Daniel;Amanat, Fatima;Krammer, Florian
通讯作者：
Krammer, Florian